Immunogenicity of current SARS-CoV-2 vaccine schedules currently used in Canada
Networks
-
Datasets
-
Variables
-
The objectives of this study are to
* Compare the immunogenicity of two vaccine doses following the standard 28 to 42-day vaccine schedule to the 4-month vaccine schedule recently used in Canada
* Determine the effect of pre-existing SARS-CoV-2 immune cross-reactivity and cCoVs (common circulating coronaviruses) antibody reactivity on the immunogenicity of the COVID-19 Vaccines
- Start Year
- 2021
- End Year
- 2023
- Supplementary Information
-
Information related this study are available at:
[Increased dosing intervals leads to increased antibody levels and neutralization](https://www.covid19immunitytaskforce.ca/increased-dosing-intervals-leads-to-increased-antibody-levels-and-neutralization/) [Why do some people experience mild COVID-19 symptoms and others have severe illness? Pre-existing antibodies could explain the range of COVID-19 illness](https://www.covid19immunitytaskforce.ca/why-do-some-people-experience-mild-covid-19-symptoms-and-others-have-severe-illness-pre-existing-antibodies-could-explain-the-range-of-covid-19-illness/) [Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy](https://gut.bmj.com/content/early/2021/11/23/gutjnl-2021-326196) If you have questions after reading the study information, please email abcovid@bcchr.ca
Visit ISVaC
| Investigators | Contacts |
|---|---|
|
|
Design
- Study design
- Cohort
- Follow Up
-
Participants are followed up eleven times: baseline, 7, 14, 28 days, 3 and 12 months post-first dose vaccination; 7, 14, 28 days, and 6 months post-second dose vaccination and 40 days post third dose vaccination.
A subset of participants had already been vaccinated when they were recruited and only had a single blood collection at 3 months post-first dose vaccination.
- Supplementary Information
- This study will recruit health care workers and use data collected from participants enrolled in the CORSIP cohort (see [CORSIP website](https://omc.ohri.ca/CORSIP/Default.aspx) for details about this cohort).
Marker Paper
Grunau B, Goldfarb DM, Asamoah-Boaheng M, et al. Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals. JAMA. 2022;327(3):279–281.
PUBMED 34860253
Recruitment
- Recruitment Target
-
- Individuals
Number of Participants
- Number of Participants
- 279
- Number of Participants with Biological Samples
- 279
- Supplementary Information
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
Timeline
ISVaC population
The population is composed of healthcare workers from British Columbia at least 18 years of age who are following a 4-month COVID-19 vaccine schedule.
Selection Criteria
- Minimum age
-
18
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Greater Vancouver Area
- Ethnic Origin
-
- Health Status
-
- Other Criteria
-
Healthcare workers are selected for this study.
Participants are excluded if they do not receive two COVID-19 vaccine doses within their vaccine schedule or if they did not receive any vaccine doses within the study period. The type of COVID-19 vaccine is limited to Pfizer//BioNTech, Moderna, Astra Zeneca, and Johnson & Johnson.
- Supplementary Information about selection criteria
Recruitment
- Sources of recruitment
-
- Specific population
- Participants from existing studies
- Specific Population
-
- Other specific population : Healthcare workers from BC
- Supplementary Information
-
Some participants are recruited from the COVID-19 Occupational Risks, Seroprevalence and Immunity among Paramedics (CORSIP).
- Participants from Existing Studies
-
- COVID-19 Occupational Risks, Seroprevalence and Immunity among Paramedics (CORSIP)
Number of Participants
- Number of Participants
- 279
- Number of Participants with Biological Samples
- 279
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 |
ISVaC - Baseline
|
Information was collected about sociodemographic characteristics (age, sex, the first three postal code digits), healthcare worker status, and history of COVID-19 symptoms, testing, and ... | 2021-01 | 2021-04 |
| 1 |
ISVaC - 7 days post-dose 1
|
Information was collected about COVID-19 vaccinations (name, date, adverse events). Blood samples were collected. | 2021-01 | 2022-01 |
| 2 |
ISVaC - 14 days post-dose 1
|
Blood samples were collected. | 2021-02 | 2021-05 |
| 3 |
ISVaC - 28 days post-dose 1
|
Blood samples were collected. | 2021-03 | 2021-05 |
| 4 |
ISVaC - 3 months post-dose 1
|
Information was collected about COVID-19 testing (test result, type of test, date of test). Blood samples were collected. | 2021-03 | 2021-08 |
| 5 |
ISVaC - 7 days post-dose 2
|
Information was collected about COVID-19 vaccinations (name, date, adverse events). Blood samples were collected. | 2022-02 | 2021-09 |
| 6 |
ISVaC - 14 days post-dose 2
|
Blood samples were collected. | 2021-03 | 2021-09 |
| 7 |
ISVaC - 28 days post-dose 2
|
Blood samples were collected. | 2021-03 | 2021-07 |
| 8 |
ISVaC - 6 months post-dose 2
|
Blood samples were collected. | 2021-11 | 2022-01 |
| 9 |
ISVaC - 40 days post-dose 3
|
Blood samples were collected. | 2022-01 | 2022-01 |
| 10 |
ISVaC - 12 months post-dose 1
|
Information was collected about COVID-19 testing (test result, type of test, date of test). Blood samples were collected. | 2022-01 | 2023-01 |
Classifications
- Socio-demographic and economic characteristics
- Lifestyle and behaviours
- Birth, pregnancy and reproductive health history
- Perception of health, quality of life, development and functional limitations
- Diseases
- Symptoms and signs
- Medication and supplements
- Non-pharmacological interventions
- Health and community care services utilization
- Death
- Physical measures and assessments
- Laboratory measures
- Cognition, personality and psychological measures and assessments
- Life events, life plans, beliefs and values
- Preschool, school and work life
- Social environment and relationships
- Physical environment
- Administrative information
Socio-demographic and economic characteristics
Age/birthdate
Sex/gender
Labour force and retirement
Diseases
Certain infectious and parasitic diseases (A00-B99)
Injury, poisoning and certain other consequences of external causes (S00-T98)
Medication and supplements
Medication and supplement intake
Posology and protocol of administration
Non-pharmacological interventions
Laboratory diagnosis interventions
Laboratory measures
Virology
Administrative information
Identifiers
Date and time-related information
Physical and cognitive measure and biosample-related information
Data and sample collection center-related information
Other administrative information